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Aim: To present, through a thorough literature research, current and older scientific efforts to 
investigate the putative association between Alzheimer’s disease (AD) and glaucoma, especially 
primary open-angle glaucoma (POAG).
Methods: We included in our review article epidemiological, experimental and clinical 
  laboratory studies.
Results: While many authors support the existence of a strong correlation between the AD 
and POAG, based on epidemiological, genetic and immunohistochemical data, others present 
contradictory results, leaving the issue unresolved.
Conclusion: Further research, probably targeted towards genetic parameters and based on 
large, multicenter studies has yet to be conducted. It is the authors’ opinion however, that the 
existing data already justify the need for at least some degree of elevated clinical alertness for 
the occurrence of AD in patients with glaucoma and of glaucoma in patients with AD.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder which is one of the main 
causes of dementia worldwide. It gradually affects all fields of cognition, including 
short and long-term memory, executional capacity and behavior. Unfortunately, despite 
advanced and intense research, no definitive therapy is currently available.1 Glaucoma, 
one of the leading causes of blindness today,2,3 with 60 million persons affected and 
8.4 million bilaterally blinded by the disease,3 is also a neurodegenerative disorder, 
characterized by degeneration of the retinal ganglion cells. The attempt to link these 
two disorders has been the focus of much research in recent years. The evidence-based 
establishment of such a connection would have a lot to offer in terms of increased clini-
cal awareness, prophylaxis and early diagnosis of dementia for glaucoma patients and 
vice versa; it would also allow novel therapeutic approaches based on the knowledge 
of common etiology or causal relationship between the two conditions.
In this review article, we have examined important recent and older articles dealing 
with the subject, both epidemiological/clinical as well as experimental, in an effort 
to clarify the problem and highlight the need for further research in this direction. 
We have focused our interest on primary open-angle glaucoma (POAG), which is the 
most common form of the disease, and which, due to its unknown etiology, is most 
likely to share common ground with AD.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Studies
epidemiological studies
Chandra et al4 reported, based on a register study of US death 
certificates, an increased prevalence of glaucoma among 
patients who died bearing the official diagnosis of senile and 
presenile dementia. More recently, Bayer et al5 announced a 
higher prevalence of glaucoma among AD patients (25.9%) 
in comparison to the prevalence observed in a control group 
of non-AD individuals (5.2%). Tamura et al6 reached the 
same conclusion based on a larger prospective study sample, 
comprised of 172 AD and 176 control individuals. The reverse 
relationship, that of an augmented occurrence of AD among 
glaucomatous patients, has also been investigated. Recently, 
Yochim et al7 found that more than 40% of a 41-person 
sample of aged glaucomatous patients showed cognitive 
impairment, in the form of either memory impairment or 
executional dysfunction, but without an official diagnosis 
of AD. This fact has implications in the ability of these 
patients to comply with an adequate antiglaucoma regimen. 
However, the relationship between dementia and glaucoma 
could not be proven in a large study (sample size more than 
11,000 subjects) performed by Kessing et al,8 which however 
had the major disadvantage of being a retrospective register-
based study. Similarly, Bach-Holm et al,9 in a recently 
published register-based study with a 20-year follow-up that 
comprised 69 normal-tension glaucoma patients reported a 
lack of correlation of this disorder with AD, as none of the 
enlisted patients developed AD.
experimental studies on animals
As a disorder in the production and deposition of Amyloid-
beta (Aβ) in the brain, amyloid plaques are characteristics 
of Alzheimer’s disease. Many researchers have focused their 
research on the role of Αβ in the development of glaucoma. 
Guo et al,10 using a rat model experimental study, induced 
augmented intraocular pressure in male rats and found 
augmented amyloid beta aggregation in the affected retinal 
ganglion cells, a finding missing in the related cells of the 
contralateral, non-affected eyes. In a similar, more recent 
study, Kipfer-Kauer et al11 managed to detect an amyloid 
regulating protein, called amyloid precursor protein (APP), 
as well as Aβ in augmented concentrations in the optic nerves 
and retinal ganglion cells of rat eyes in which ocular hyper-
tension was surgically induced. McKinnon12 also worked 
with a rat glaucoma experimental model, elucidating the 
role of apoptotic cell death through activation of a family 
of proteases, called caspases. These proteolytic enzymes 
(especially caspase-3 and caspase-8) act on APP to cause 
the production of neurotoxic fragments, which include 
Aβ, thus providing an extra pattern of common etiology 
between AD and glaucoma at the cellular level. Vickers13 
has also emphasized the role of cellular damage and cellular 
reaction to stress in the development of AD and glaucoma; 
He focused his studies on the neurofilament triplet, a group 
of cytoskeletal proteins accumulated in cases of damage to 
the larger retinal ganglion cells.
Clinical-laboratory studies on humans
A very interesting study that added a lot to the elucidation 
of the putative association between Alzheimer’s disease and 
glaucoma was conducted by Gupta et al.14 The researchers 
used human ocular tissue specimens gained during   glaucoma 
operations, and compared their immunohistochemical 
  characteristics to those of living and postmortem control 
tissue specimens. They found that patients with unregulated 
intraocular pressure had decreased concentrations of   normal 
tau-protein (BT2) and increased presence of abnormal hyper-
phosphorylated tau-protein molecules (AT8),   especially 
within the posterior retina; such molecules can also be 
detected in the cerebrospinal fluid (CSF) of AD patients. In 
another clinical-laboratory study, Yoneda et al15 measured the 
Aβ 42 and tau-protein levels of the vitreous fluid in patients 
with retinal pathologies undergoing vitrectomy (including 
glaucomatous patients) and compared them to those of con-
trol patients. Patients with glaucoma had decreased levels 
of Aβ and increased levels of tau-proteins in their vitreous 
fluid. This finding is possibly linked to the decreased levels 
of Aβ and increased levels of tau-proteins in the CSF of 
AD patients.
Another possible link between AD and glaucoma lies 
in the CSF pressure, which appears to be decreased in AD 
patients, a fact also observed among POAG patients.16 Ren 
et al, in two recent studies,17,18 which recruited patients with 
high-tension glaucoma, normal-tension glaucoma, patients 
with intraocular pressure without glaucoma and healthy 
  subjects, highlighted the importance of the translamina-
cribrosa pressure difference in the development of at least one 
of the characteristic optic nerve damages of glaucoma, loss 
of neuroretinal rim (the others being deepening of the optic 
cup and parapapillary atrophy), and of the subsequent visual 
deficits. The translamina-cribrosa pressure difference may 
be a combination of normal intracranial/intraocular pressure 
and decreased CSF pressure or of an elevated intracranial/
intraocular pressure and normal CSF pressure. Berdahl and 
Allingham19 also highlighted the importance of reduced 
CSF pressure in the pathogenesis of glaucoma, in addition Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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to the significance of elevated intracranial pressure in cases 
of high-tension glaucoma. Elevated intracranial pressure is 
also considered as a characteristic finding in AD. Wostyn 
et al22 addressed the quite complex issue of CFS pressure, 
AD and glaucoma: they correlated early stages of AD with 
elevated CSF pressure and later stages with decreased CSF 
pressure. They also highlighted the importance of a high 
translamina-cribrosa pressure difference in the development 
of glaucoma.20–22
Apolipoprotein e gene and glaucoma
An additional field of research into links between AD and 
glaucoma focuses on the apolipoprotein (APOE) gene and its 
variations. The gene is implicated in brain cholesterol and 
amyloid metabolism, and its APOE-ε4 variation is regarded 
as one of the major predisposing factors for the development 
of AD.23 It is also responsible for decreased capacity of nerve 
cells in response to stress and for delayed rehabilitation 
after stroke or head trauma.24–26 This is the reason that many 
  scientists have worked on the putative association of the gene 
with glaucoma. Zetterberg et al27 focused on the issue in a 
study of over 400 subjects and found no such correlation. 
Tamura et al,6 Ressiniotis et al,28 and Lake et al29 in older 
similar studies also obtained negative results, even for normal 
tension glaucoma, which would theoretically leave more 
“room” for genetic factors like APOE to work as glaucoma 
precipitating factors.
Al-Dabbagh et al,30 on the contrary, in a study performed 
on 230 Saudi individuals, found a positive correlation 
between the Apoe-ε4 allele and the development of primary 
open-angle glaucoma, and, in addition, found a protective 
role of the ε-3 allele against the disease. Saglar et al31 also 
performed a genetic study on 75 patients with POAG and 
119 control individuals and found no correlation between 
the polymorphisms of the APOE, tumor suppressor protein 
53 (p53) and cyclin-dependent kinase inhibitor 1A (p21) 
genes on one hand and POAG on the other. However, Lam 
and associates32 concluded in a genetic study performed on 
400 Chinese individuals that APOE–ε4 is associated with 
glaucoma, but by acting as a protective factor against it.
Pseudoexfoliation glaucoma is a form of secondary 
  glaucoma, which is characterized by ocular accumulation 
of fibrils containing amyloid-related proteins, thus   probably 
sharing common features with AD. Krumbiegel et al33 
however, in a meta-analysis comprising two European (one 
German and one Italian) cohorts, with over 1000 participants, 
found a negative correlation between APOE polymorphisms 
and this disorder.
Conclusion
Many important studies have supported the connection 
between AD and POAG. These data derive from epide-
miological, experimental and clinical laboratory studies. 
These results, however, are contradicted by a series of other 
equally significant studies: this shows that the etiology of 
both AD and POAG is complex and warrants further focused 
investigation.
The existing data justify an elevated level of clinical 
awareness for the diagnosis of glaucoma in AD patients 
and vice versa. Hopefully, future research will shed light 
on the issue to the benefit of these two large categories of 
patients.
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